Abstract
Artificial intelligence (AI)-based diagnostic algorithms have achieved ambitious aims through automated image pattern recognition. For neurological disorders, this includes neurodegeneration and inflammation. Scalable imaging technology for big data in neurology is optical coherence tomography (OCT). We highlight that OCT changes observed in the retina, as a window to the brain, are small, requiring rigorous quality control pipelines. There are existing tools for this purpose. Firstly, there are human-led validated consensus quality control criteria (OSCAR-IB) for OCT. Secondly, these criteria are embedded into OCT reporting guidelines (APOSTEL). The use of the described annotation of failed OCT scans advances machine learning. This is illustrated through the present review of the advantages and disadvantages of AI-based applications to OCT data. The neurological conditions reviewed here for the use of big data include Alzheimer disease, stroke, multiple sclerosis (MS), Parkinson disease, and epilepsy. It is noted that while big data is relevant for AI, ownership is complex. For this reason, we also reached out to involve representatives from patient organizations and the public domain in addition to clinical and research centers. The evidence reviewed can be grouped in a five-point expansion of the OSCAR-IB criteria to embrace AI (OSCAR-AI). The review concludes by specific recommendations on how this can be achieved practically and in compliance with existing guidelines.
Original language | English |
---|---|
Pages (from-to) | 1528-1542 |
Number of pages | 15 |
Journal | Annals of Clinical and Translational Neurology |
Volume | 8 |
Issue number | 7 |
DOIs | |
Publication status | Published - Jul 2021 |
Externally published | Yes |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Annals of Clinical and Translational Neurology, Vol. 8, No. 7, 07.2021, p. 1528-1542.
Research output: Contribution to journal › Review Article › Research › peer-review
TY - JOUR
T1 - Artificial intelligence extension of the OSCAR-IB criteria
AU - Petzold, Axel
AU - Albrecht, Philipp
AU - Balcer, Laura
AU - Bekkers, Erik
AU - Brandt, Alexander U.
AU - Calabresi, Peter A.
AU - Deborah, Orla Galvin
AU - Graves, Jennifer S.
AU - Green, Ari
AU - Keane, Pearse A.
AU - Nij Bijvank, Jenny A.
AU - Sander, Josemir W.
AU - Paul, Friedemann
AU - Saidha, Shiv
AU - Villoslada, Pablo
AU - Wagner, Siegfried K.
AU - Yeh, E. Ann
AU - Aktas, Orhan
AU - Antel, Jack
AU - Asgari, Nasrin
AU - Audo, Isabelle
AU - Avasarala, Jagannadha
AU - Avril, Daly
AU - Bagnato, Francesca R.
AU - Banwell, Brenda
AU - Bar-Or, Amit
AU - Behbehani, Raed
AU - Manterola, Arnaldo Belzunce
AU - Bennett, Jeffrey
AU - Benson, Leslie
AU - Bernard, Jacqueline
AU - Bremond-Gignac, Dominique
AU - Britze, Josefine
AU - Burton, Jodie
AU - Calkwood, Jonathan
AU - Carroll, William
AU - Chandratheva, Arvind
AU - Cohen, Jeffrey
AU - Comi, Giancarlo
AU - Cordano, Christian
AU - Costa, Silvana
AU - Costello, Fiona
AU - Courtney, Ardith
AU - Cruz-Herranz, Anes
AU - Cutter, Gary
AU - Crabb, David
AU - Delott, Lindsey
AU - De Seze, Jerome
AU - Diem, Ricarda
AU - Dollfuss, Helene
AU - El Ayoubi, Nabil K.
AU - Fasser, Christina
AU - Finke, Carsten
AU - Fischer, Dominik
AU - Fitzgerald, Kathryn
AU - Fonseca, Pedro
AU - Frederiksen, Jette L.
AU - Frohman, Elliot
AU - Frohman, Teresa
AU - Fujihara, Kazuo
AU - Cuellar, Iñigo Gabilondo
AU - Galetta, Steven
AU - Garcia-Martin, Elena
AU - Giovannoni, Gavin
AU - Glebauskiene, Brigita
AU - Suárez, Inés González
AU - Jensen, Gorm Pihl
AU - Hamann, Steffen
AU - Hartung, Hans Peter
AU - Havla, Joachim
AU - Hemmer, Bernhard
AU - Huang, Su Chun
AU - Imitola, Jaime
AU - Jasinskas, Vytautas
AU - Jiang, Hong
AU - Kafieh, Rahele
AU - Kappos, Ludwig
AU - Kardon, Randy
AU - Keegan, David
AU - Kildebeck, Eric
AU - Kim, Ungsoo Samuel
AU - Klistorner, Sasha
AU - Knier, Benjamin
AU - Kolbe, Scott
AU - Korn, Thomas
AU - Krupp, Lauren
AU - Lagrèze, Wolf
AU - Leocani, Letizia
AU - Levin, Netta
AU - Liskova, Petra
AU - Preiningerova, Jana Lizrova
AU - Lorenz, Birgit
AU - May, Eugene
AU - Miller, David
AU - Mikolajczak, Janine
AU - Saïd, Saddek Mohand
AU - Montalban, Xavier
AU - Morrow, Mark
AU - Mowry, Ellen
AU - Murta, Joaquim
AU - Navas, Carlos
AU - Nolan, Rachel
AU - Nowomiejska, Katarzyna
AU - Oertel, Frederike Cosima
AU - Oh, Jiwon
AU - Oreja-Guevara, Celia
AU - Orssaud, Christophe
AU - Osborne, Benjamin
AU - Outteryck, Olivier
AU - Paiva, Catarina
AU - Palace, Jacky
AU - Papadopoulou, Athina
AU - Patsopoulos, Nikos
AU - Preiningerova, Jana Lizrova
AU - Pontikos, Nikolas
AU - Preising, Markus
AU - Prince, Jerry
AU - Reich, Daniel
AU - Rejdak, Robert
AU - Ringelstein, Marius
AU - Rodriguez de Antonio, Luis
AU - Sahel, Jose Alain
AU - Sanchez-Dalmau, Bernardo
AU - Sastre-Garriga, Jaume
AU - Schippling, Sven
AU - Schuman, Joel
AU - Shindler, Ken
AU - Shin, Robert
AU - Shuey, Neil
AU - Soelberg, Kerstin
AU - Specovius, Svenja
AU - Suppiej, Agnese
AU - Thompson, Alan
AU - Toosy, Ahmed
AU - Torres, Rubén
AU - Touitou, Valérie
AU - Trauzettel-Klosinski, Susanne
AU - van der Walt, Anneke
AU - Vermersch, Patrick
AU - Vidal-Jordana, Angela
AU - Waldman, Amy T.
AU - Waters, Christian
AU - Wheeler, Russell
AU - White, Owen
AU - Wilhelm, Helmut
AU - Winges, Kimberly M.
AU - Wiegerinck, Nils
AU - Wiehe, Lenja
AU - Wisnewski, Thomas
AU - Wong, Sui
AU - Würfel, Jens
AU - Yaghi, Shadi
AU - You, Yuyi
AU - Yu, Zhaoxia
AU - Yu-Wai-Man, Patrick
AU - Žemaitienė, Reda
AU - Zimmermann, Hanna
AU - the IMSVISUAL, ERN-EYE Consortium
N1 - Funding Information: A. Petzold is part of the steering committee of the ANGI network which is sponsored by ZEISS, steering committee of the OCTiMS study which is sponsored by Novartis, and reports speaker fees from Heidelberg Engineering. P. Albrecht reports consulting fees, research grants, and nonfinancial support from Allergan, Biogen, Celgene, Ipsen, Merck Serono, Merz Pharmaceuticals, Novartis, and Roche, consulting fees, and nonfinancial support from Bayer Healthcare, and Sanofi‐Aventis/Genzyme, outside the submitted work. L. Balcer reports personal fees from Biogen; she is editor in chief of the Journal of Neuro‐Ophthalmology. E. Bekkers has nothing to disclose. A. Brandt is cofounder and shareholder of startups Motognosis and Nocturne. He is named as inventor on several patent applications description MS serum biomarkers, perceptive visual computing, and retinal image analysis. R. Bremel has served as a consultant for Biogen, EMD Serono, Genzyme/Sanofi, Genentech/Roche, Novartis, and Viela Bio. He receives ongoing research support directed to his institution from Biogen, Genentech, and Novartis. P.A. Calabresi has received consulting fees for serving on scientific advisory boards for Biogen and Disarm Therapeutics, and is PI on grants to Johns Hopkins from Biogen, Gentech, and Annexon. O. Galvin has nothing to disclose. J.S. Graves has grant/contract research support from the National MS Society, Biogen, and Octave Biosciences. She serves on a steering committee for a trial supported by Novartis. She has received honoraria for a nonpromotional, educational activity for Sanofi‐Genzyme. She has received speaker fees from Alexion and BMS and served on an advisory board for Genentech. A. Green reports grants and other support from Inception Biosciences; grants from the National Multiple Sclerosis Society and from the US. National Institutes of Health; additional support from MedImmune, Mylan, Sandoz, Dr Reddy, Amneal, Momenta, Synthon, and JAMA Neurology, outside the submitted work; and that the Multiple Sclerosis Center, Department of Neurology, University of California San Francisco has received grant support from Novartis for participating in the OCTIMS study. P.A. Keane is supported by a Clinician Scientist award (CS‐2014‐14‐023) from the National Institute for Health Research. J. Nij Bijvank has nothing to disclose. J.W. Sander has been consulted by and received research grants and fees for lectures from Eisai, UCB, Zogenix, and GW Pharmaceuticals, outside the submitted work. F. Paul receives funding from Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, and Guthy Jackson Charitable Foundation. FC has received consulting fees from Clene, EMD Serono, and PRIME, and is participating as a site investigator in the Novartis‐funded OCTIMS study. S. Saidha has received consulting fees from Medical Logix for the development of CME programs in neurology and has served on scientific advisory boards for Biogen‐Idec, Genzyme, Genentech Corporation, EMD Serono, and Celgene. He was the site investigator of a trial sponsored by MedDay Pharmaceuticals, and is the PI of investigator‐initiated studies funded by Genentech Corporation and Biogen Idec, and received support from the Race to Erase MS foundation. He has received equity compensation for consulting from JuneBrain LLC, a retinal imaging device developer. P. Villoslada has received an honorarium from Heidelberg Engineering in 2014, has received unrestricted research grants from Novartis (including for the OCTIMS study), Biogen, Genzyme, and Roche, and has participated in advisory boards for Novartis, Roche, Genzyme, and Biogen. PVi holds stocks in the following spin‐off companies: Bionure Inc, Spire Bioventures, Mintlabs, and Health Engineering. S. Wagner has nothing to disclose. E. Ann Yeh has received research funds from NMSS, CIHI, CIHR, NIH, OIRM, MS Society of Canada, Mario Battaglia Foundation, SickKids Foundation, CBMH Innovation Fund, CMSC, Stem Cell Network, Department of Defense, Rare Diseases Foundation, and Biogen. Unrestricted educational funds from Teva and Guthy‐Jackson Foundation. She has served on a scientific advisory panel for Hoffmann‐La Roche and Biogen and has received speaker’s honoraria from Novartis, CMSC, MS at the Limits, and Canadian Rheumatological Association. Funding Information: We (AP and PAK) acknowledge a proportion of our financial support from the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. JWS is based at the NIHR University College London Hospitals Biomedical Research Centre, which receives a proportion of funding from the UK Department of Health’s Biomedical Research Centres’ funding scheme. He receives support from the UK Epilepsy Society, the Dr. Marvin Weil Epilepsy Research Fund and the Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie, Netherlands. JNB is supported by the Dutch MS Research Foundation, grant nr. 18‐1027. SW is supported by the Medical Research Council through a Clinical Research Training Fellowship. Publisher Copyright: © 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/7
Y1 - 2021/7
N2 - Artificial intelligence (AI)-based diagnostic algorithms have achieved ambitious aims through automated image pattern recognition. For neurological disorders, this includes neurodegeneration and inflammation. Scalable imaging technology for big data in neurology is optical coherence tomography (OCT). We highlight that OCT changes observed in the retina, as a window to the brain, are small, requiring rigorous quality control pipelines. There are existing tools for this purpose. Firstly, there are human-led validated consensus quality control criteria (OSCAR-IB) for OCT. Secondly, these criteria are embedded into OCT reporting guidelines (APOSTEL). The use of the described annotation of failed OCT scans advances machine learning. This is illustrated through the present review of the advantages and disadvantages of AI-based applications to OCT data. The neurological conditions reviewed here for the use of big data include Alzheimer disease, stroke, multiple sclerosis (MS), Parkinson disease, and epilepsy. It is noted that while big data is relevant for AI, ownership is complex. For this reason, we also reached out to involve representatives from patient organizations and the public domain in addition to clinical and research centers. The evidence reviewed can be grouped in a five-point expansion of the OSCAR-IB criteria to embrace AI (OSCAR-AI). The review concludes by specific recommendations on how this can be achieved practically and in compliance with existing guidelines.
AB - Artificial intelligence (AI)-based diagnostic algorithms have achieved ambitious aims through automated image pattern recognition. For neurological disorders, this includes neurodegeneration and inflammation. Scalable imaging technology for big data in neurology is optical coherence tomography (OCT). We highlight that OCT changes observed in the retina, as a window to the brain, are small, requiring rigorous quality control pipelines. There are existing tools for this purpose. Firstly, there are human-led validated consensus quality control criteria (OSCAR-IB) for OCT. Secondly, these criteria are embedded into OCT reporting guidelines (APOSTEL). The use of the described annotation of failed OCT scans advances machine learning. This is illustrated through the present review of the advantages and disadvantages of AI-based applications to OCT data. The neurological conditions reviewed here for the use of big data include Alzheimer disease, stroke, multiple sclerosis (MS), Parkinson disease, and epilepsy. It is noted that while big data is relevant for AI, ownership is complex. For this reason, we also reached out to involve representatives from patient organizations and the public domain in addition to clinical and research centers. The evidence reviewed can be grouped in a five-point expansion of the OSCAR-IB criteria to embrace AI (OSCAR-AI). The review concludes by specific recommendations on how this can be achieved practically and in compliance with existing guidelines.
UR - http://www.scopus.com/inward/record.url?scp=85105998632&partnerID=8YFLogxK
U2 - 10.1002/acn3.51320
DO - 10.1002/acn3.51320
M3 - Review Article
C2 - 34008926
AN - SCOPUS:85105998632
SN - 2328-9503
VL - 8
SP - 1528
EP - 1542
JO - Annals of Clinical and Translational Neurology
JF - Annals of Clinical and Translational Neurology
IS - 7
ER -